Listed pharmaceuticals ‘increase’ R&D investments, but ‘decrease’ its ratios to sales

Published: 2015-12-02 14:01:29

Updated: 2015-12-02 14:01:29

Although the 3^rd quarter’s collective R&D expenses of listed pharmaceutical companies increased this year compared with the same quarter of the last year, the average ratio to sales was decreased in the KOSPI and KOSDAQ both.

In each category, companies with the 3^rd quarter’s largest R&D expenses were Hanmi Pharm in the KOSPI and Huons in the KOSDAQ, and companies with the largest growth ratio...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.

Listed pharmaceuticals ‘increase’ R&D investments, but ‘decrease’ its ratios to sales

Although the 3rd quarter’s collective R&D expenses of listed pharmaceutical companies increased this year compared with the same quarter of the last year, the average ratio to sales was decreased in the KOSPI and KOSDAQ both.

Fees

Although the 3^rd quarter’s collective R&D expenses of listed pharmaceutical companies increased this year compared with the same quarter of the last year, the average ratio to sales was decreased in the KOSPI and KOSDAQ both.